---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-167962"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2024-06-25T23:59:59+00:00"
generated_at: "2026-06-01T02:10:34.511675+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Annexon Phase 3 trial of ANX005 meets primary endpoint; GBS patients recover faster

## Summary
- Primary endpoint at Week 8: 2.41-fold higher likelihood of better health state (p=0.0058).
- ANX005 patients walked 31 days earlier and came off ventilation 28 days earlier vs placebo.
- At Week 26, 21.5% of ANX005 patients fully recovered (GBS-DS=0) vs 8.6% on placebo (OR 4.14, p=0.0092).
- Subgroup with North American/European baseline characteristics showed 3x greater likelihood of better health state at Week 8.
- Single infusion generally well-tolerated; safety profile similar to placebo, no increased infections.

## SEC filing metadata
- accession: 0001193125-24-167962
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2024-06-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000119312524167962/0001193125-24-167962-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000119312524167962/d822308d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-167962
- JSON: https://secwatch.observer/filing/0001193125-24-167962.json
- Plain text: https://secwatch.observer/filing/0001193125-24-167962.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.